Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Shake Up Continues With Key Exits From Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker

You may also be interested in...



Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China

The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.

Pfizer On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 2 of 2)

On the way back to his old job in the U.S., after a stint in Shanghai as head of research in Asia, VP Richard Connell, head of Preclinical Outsourcing says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

Pfizer Head of Preclinical Outsourcing VP Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 1 of 2)

On the way back to his old job in the U.S., after a stint in Shanghai as head of research Asia, Richard Connell says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.

Related Content

UsernamePublicRestriction

Register

SC073772

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel